PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
42.82M
Worse than BTAI's estimated revenue of 195.50M.
-8.56M
Better than BTAI's estimated ebitda of -39.10M.
-0.59
Better than BTAI's estimated eps of -0.80.
-17.89M
Worse than BTAI's estimated net income of -2.03M.
-8.56M
Better than BTAI's estimated ebit of -39.10M.
1.59B
Better than BTAI's estimated sg&a expense of 10.21B.
Analyze DCF forecasts for the company and compare them with competitors.
81.00K
Worse than BTAI's revenue of 1.38M.
-92.14%
Worse than BTAI's revenue growth rate of 268.00%.
-51.13M
Better than BTAI's ebitda of -165.42M.
-63123.46%
Worse than BTAI's ebitda margin of -11987.03%.
-51.92M
Better than BTAI's ebit of -165.74M.
-64098.77%
Worse than BTAI's ebit margin of -12010.07%.
790.00K
Worse than BTAI's depreciation of 318.00K.
76.68M
Better than BTAI's total cash of 65.22M.
94662.96%
Better than BTAI's cash as percentage of revenue of 4726.16%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
7.95M
Better than BTAI's accounts payable of 13.65M.
9818.52%
Worse than BTAI's payables as percentage of revenue of 989.42%.
-153.00K
Better than BTAI's capital expenditure of -20.00K.
-188.89%
Better than BTAI's capex as percentage of revenue of -1.45%.
4.99%
Better than BTAI's weighted average cost of capital (wacc) of 14.36%.
5.02%
Worse than BTAI's cost of equity of 5.00%.
4.08%
Better than BTAI's cost of debt of 14.70%.
-0.23
Better than BTAI's beta of 0.08.
30.07M
Worse than BTAI's diluted shares outstanding of 2.54M.
1.57M
Better than BTAI's total debt of 102.95M.
49.31M
Better than BTAI's total equity of 3.68M.
50.89M
Worse than BTAI's total capital of 106.62M.
3.09%
Better than BTAI's debt weighting of 96.55%.
96.91%
Better than BTAI's equity weighting of 3.45%.
-51.92M
Better than BTAI's ebiat of -165.74M.
-53.46M
Better than BTAI's unlevered free cash flow of -161.84M.
2.00%
Equal to BTAI's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than BTAI's net debt of 73.09M.
71.33M
Better than BTAI's equity value of -68.25M.
2.37
Better than BTAI's equity value per share of -26.92.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.